Genmab — Februar 2020

[Darvin]

OFA:
http://www.haematologica.org/content/early/2020/01/27/haematol.2019.235705

[GeorgeBest]

Dette link fra Rajkumar bekræfter hvad Bulder skriver. Kun 11% af læger vil bruge DRd i 1. linie https://twitter.com/vincentrk/status/1223263850956386304?s=21

[Hugininvest]

Detalje: den slags afstemninger er ikke troværdige. Selv jeg har stemt - så hvor mange læger og hvor mange spøgefugle har mon gjort det

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

https://m.firstwordpharma.com/vaccine-work-novel-coronavirus-advances

[Helge_LarsenPI-redaktør]

Der er udsigt til en indledende nervøs dansk aktiehandel med mindre fald. Der er dog ikke udsigt til nogen meget negativ start. Dels har aktierne allerede reageret lidt på Corona og dels er smitten trods alt koncentreret i Kina. https://blog.nordnet.dk/kinesisk-aktiepanik/?fbclid=IwAR2uFmmTg2dY_EngYOZADiYu-upTuHDoDQC5Bbv3G3IYJBJOxbcD8QdALHE

[transalp]

Go morgen.

[Helge_LarsenPI-redaktør]

CNBC
·

US futures point to higher open despite coronavirus fears. https://www.cnbc.com/2020/02/03/us-futures-point-to-higher-open-despite-coronavirus-fears.html?__source=twitter|main

[Hamming]

Antibody-drug conjugates on the march

One of AstraZeneca’s most decisive moves last year came when it signed a multi-billion dollar deal with Daiichi Sankyo, focused on just one breast cancer drug. We spoke with Daiichi's Gilles Gallant about the future plans for the drug, and the antibody-drug conjugate technology behind it

pharmaphorum (pharmaphorum.com)

[Hamming]

Lidt interessant ift. Genmabs ADC´er

[Hamming]

Daiichi mener også, at der er plads/brug for ADC´er

[Sukkeralf]

Ligeledes Zymeworks som med ZW49 har en direkte konkurrent til DS8201 - blot med et bispecifikt ADC.

[gentogen]

Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. Journal of Geriatric Oncology
Volume 11, Issue 1, January 2020

[gentogen]

ofatumumab may represent an additional option to treat post-transplant FSGS relapse in patients who respond poorly to rituximab. Our experience suggests that its effectiveness could be related to prolonged depletion of potentially pathogenic switched memory B cells. Pediatric Nephrology volume 35, pages341–345(2020)

[gentogen]

Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness. Ofatumumab could be a safe and cost/effective rescue therapy for patients with MN sensitised against rituximab. BMJ CVase Reports

[GeorgeBest]

Er der et nyt marked for Ofa i CLL?

[GeorgeBest]

Jeg troede at Ofa var en død sild i cancer?

[bikube]

Flot luk i dagens højeste 1579,50

[JKY_VH]

tak gentogen

[Darvin]

Ja - Noget kunne tyde på at vi også skal se efter OFA i Call. Linket fra imorges omhandlerogså OFA’s resultater.